IL6 and glioblastoma: Combined IL-6 and PD-1 blockade remodels the tumor microenvironment towards an antitumoral phenotype, albeit transiently, and improves survival in an allograft murine model of glioblastoma whose tumor microenvironment resembles that of the human disease (23).